Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD

29 May 2024

Abstract excerpt

Accurate non-invasive biomarkers to diagnose metabolic dysfunction-associated steatotic liver disease (MASLD)-related fibrosis are urgently needed. This study applies a translational approach to develop a blood-based biomarker panel for fibrosis detection in MASLD. A molecular gene expression signature identified from a diet-induced MASLD mouse model (LDLr-/-.Leiden) is translated into human blood-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic and Kidney Cyst Diseases
Share to Liver Disease Diagnosis and Treatment
Share to Liver Diseases and Immunity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38811591
DOI: 10.1038/s41467-024-48956-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLDPMID 38811591Read ↗

Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progressionSemantic proximity Read ↗

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progressionSemantic proximity Read ↗

Integrative multi-omics and multi-trait analysis prioritizes regulatory mechanisms and genes for metabolic dysfunction-associated steatotic liver diseaseSemantic proximity Read ↗

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liverSemantic proximity Read ↗

Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical applicationSemantic proximity Read ↗

Biomarker Discovery for Metabolic Dysfunction-associated Steatotic Liver Disease Utilizing Mendelian Randomization, Machine Learning, and External ValidationSemantic proximity Read ↗

Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsSemantic proximity Read ↗

Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver DiseaseSemantic proximity Read ↗

UK Biobank-Based Genetic and Proteomic Network Insights into Metabolic Dysfunction-Associated Steatotic Liver Disease Pathogenesis.Semantic proximity Read ↗

A proteo-transcriptomic map of non-alcoholic fatty liver disease signaturesSemantic proximity Read ↗

MegaMASLD: An interactive platform for exploring stratified transcriptomic signatures in MASLD progressionSemantic proximity Read ↗

The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.